All right. Welcome to day two of the Stephens Conference. I'm Mason Carrico, the Diagnostics and Med Tech Analyst here. Happy to have Vericel with us today. We've got Nick Colangelo, CEO, Joe Mara, CFO. Appreciate you guys coming.
Thanks, Mason. Good to be here.
Thanks for having us.
Maybe just start, I guess we can hit on Q3 results. You guys just reported the quarter. Maybe just a quick overview. What are the key highlights? What are the main takeaways you want investors to come away with following the print?
Yeah, I will start with that one. Just before we begin, I will just remind everybody that we will be making forward-looking statements during this presentation, so you should check on our documents on file with the SEC for further information. Thanks for letting me get that out of the way. We reported a couple weeks ago, as you mentioned, and we really had an outstanding third quarter, which arguably was the strongest quarter of the year for the company, for MACI, for burn care, in that we generated top-tier revenue growth, inflection in profitability, and really strong cash flow. We delivered record third quarter revenue of more than $85 million, which increased 26% versus prior year, which exceeded our guidance for the quarter. MACI revenue was really strong, over $67 million, which was up 21%.
Same thing with burn care, where we had the highest burn care revenue in history, and each of the products had their highest quarterly revenues as well. Just really strong revenue performance, and of course, really strong profitability performance as well, with strong gross margins. We had net income tripled in the quarter versus the prior year. We had adjusted EBITDA increasing nearly 50% to almost $25 million, and we had really strong operating and free cash flow. That dimension was very strong as well, and really continued when you looked at the year-to-date numbers. They were remarkably similar year- to- date as they were in the third quarter, both on the revenue and profitability metrics. A continuation of really multiple quarters of great performance.
I think the encouraging part of that is that our third quarter performance, really all year, has been driven by really strong execution on the commercial side, as well as significant momentum in the underlying business drivers, and I am sure we will cover that as we go forward. That is what really gave us confidence around saying that October was great, was in the books by the time we got to our earnings call, and really set us up well for a strong close to the year and strong growth into 2027 and beyond.
Mm-hmm. Joe, maybe one for you here. MACI guidance was raised. I think what you may have said is something along the lines of there could be upside to Q4 procedure trends from the start of the quarter continued into December. Maybe just give us some color on what you are seeing from the procedure volumes, from a procedure volume standpoint, the positive early indicators for December, and how we should be thinking about how that translates into Q4.
Yeah, I mean, as Nick said broadly, the execution has been very strong. The biopsy trends continue to be very strong into the fourth quarter, which is exactly what we want to see. We had the call a couple of weeks ago and pointed to that guidance, which was an increase in our Q4 guidance to over 20%. I would say, we obviously have October behind us. We are a little farther through November now, and I would say that is certainly trending to a very strong close. Then again, I would say our indicators on December thus far also remain quite strong a couple weeks out from our earnings.
As Nick said, we feel like we are continuing to be set up for a strong close to the year, but also importantly, as we turn into next year, with what we have seen from biopsy growth, we think that is going to set us up very well to start next year as well.
Mm-hmm. Okay. Maybe taking a higher level view here, I guess. Nick, I think it may have been you said main goal of the sales force expansion and some of these commercial initiatives is driving deeper penetration within MACI surgeon practice. I guess, what are reps doing differently inside of practice today than maybe they were two years ago?
Yeah, I mean, we talked a lot about the growth has been driven, I guess, by three factors that we have mentioned. One is we increased the sales force effective as of January 1 this year. Last year, we implemented a number of commercial excellence initiatives that were really put in place for Q1 as well, and then of course, you have contribution from MACI Arthro, which has gained momentum. I would say one of the key drivers on the commercial excellence side is sort of, we have data now that we can look in great detail at sort of the surgeon procedural volumes, and what we kind of talk about is qualifying cartilage repair procedures for each surgeon that we target.
That really helped us to resegment the surgeons so that we could have our reps focused on the highest potential surgeons and really drive the business. That was all around deeper penetration. We have always had strong growth from new surgeon adds, and that has continued. When we talk about biopsy growth, for instance, in years past, it was more about more surgeons, same average biopsies per surgeon, you just get more surgeons and more biopsy growth. Since last year, it has really been a more balanced sort of contribution of increased in biopsying surgeons, so breadth of the surgeon base, but also more biopsies per surgeon, which leads to more implants per surgeon, and that is really what is contributing to the growth.
When you segment surgeons, they fall into a bunch of different categories, but in the growth sort of category, you can have sort of biopsy growth surgeons. They have a lot of qualifying procedures, but they could be taking more biopsies. What is a play to run to sort of make that happen based on kind of standardized best practices? It could be a surgeon who is already taking high volumes of biopsies, but maybe not converting at the same rate, so how do you get those conversions up? Each of those sort of drives deeper penetration into the surgeons, and that is kind of really what we have done that is different from what reps used to do. It is more systematic. I mean, obviously reps were doing these things.
But again, when you have sort of standardization across the entire sales force, particularly as we were expanding by 30%, it was really important as we took a step back and said, "Happy that we got to a quarter billion in revenue. What do we have to do and what do we need to do differently to get to our midterm targets of half a billion in revenue?
This was all part of that initiative.
How have overall MACI conversion rates trended throughout 2026? I think at the beginning of the year, you may have mentioned smaller territories, it's lifted biopsy pull through, maybe there's potential for conversion rates to improve. I guess, how has that trended throughout 2026? How does it look compared to 2025?
Yep. I would separate out two things. One, we said early in the year, and even on our third quarter call, because it's remained true, that the new territories, which have new sales reps, have had the highest biopsy growth rate in the first quarter and then all the way now through the third quarter, and that sort of makes sense. Your new rep, you walk into a new territory, these are not white space territories. There's already a book of business there's biopsies, so what would you want to see in Q1 of this year? Reps pulling through those biopsies into implant and then building their pipeline as they move forward. So having, they did a good job on both. Their biopsy growth rates increased in the second quarter and then continued to be strong in the third quarter.
That sets them up for a good, those new territories, to have a good strong close to the year and a pipeline into 2027 and beyond. In terms of the conversion rate, that's really been pretty stable in 2026, as it has been. We talk a lot about the underlying dynamics, where roughly a third of biopsies end up converting over an 18-month or two-year period, and that's at an aggregate level. But underneath that, what you see is surgeons who are more experienced or have a higher volume of MACI implants tend to have much higher conversion rates.
Probably more like 50%. Then we have a lot of new surgeons coming into the fold who have, when they start using MACI, lower conversion rates, because you could take a biopsy, your first patient may not come back for surgery for six, nine, 12 months, your conversion rate's zero. So it kind of nets out to a stable conversion rate. But again, a couple of things. One, when you're a more experienced MACI user, your conversion rate's higher. Two, we've mentioned on our calls that if you're a MACI Arthro implanter, you tend to have a higher conversion rate and higher utilization with MACI Arthro cases and MACI open cases.
Even with sort of those growth segments that we talked about, when we have gotten the reps focused this year on sort of that segment of grow your implants because you already have a lot of biopsies, we are seeing higher conversion rates out of those surgeons. Again, these are all smaller pieces of the big picture or the overall trend, so they tend to get subsumed a little bit, but those are exactly the kind of trends you want to see for the initiatives that we have implemented over the last year.
Okay. For surgeons, I guess, who are taking a lot of biopsies but maybe do not convert at a high rate, what is the playbook to drive implant conversions with that surgeon group? I guess, as you kind of look at your surgeon base today, how many fall into that category broadly?
Yeah, I mean, we have not given sort of subsets of different surgeon segments and things like that, but I would just say kind of at a high level, for every sort of segment that is either they are already doing lots of implants and you want to protect that business or sort of they may not be your highest target, but for some reason they engage and you sort of react to those surgeons within those growth categories, which is, are the other segments. If it happens to be, if you looked at the qualifying procedures and you say, "Wow, there is a lot of procedures there, that is why they are a target, and they are already taking a lot of biopsies, why are not they converting at the same rate or as high as others in that segment?" It usually falls into one of two buckets.
There is either some administrative barrier or some clinical barrier. If it is administrative barrier, it could be something like working with the office staff. We do the benefits coordination with our case managers, working with the office staff to gather the information, to get the PAs prior approval submission, and so on, and just those sort of administrative things to unlock those biopsies and help them convert. It could be that there is more of a clinical sort of opportunity there where you can go in and have a conversation of, "Hey, surgeon, when you have a patient with a biopsy of this size and this location of the knee, here are publications that demonstrate clinical outcomes for treating that patient." It really depends on sort of the nature of that particular surgeon or practice, but that is kind of what they do.
It's playbooks along those lines that were, again, these weren't things we just made up. When we developed the segments and then sort of developed the plays to move the needle in those segments, it was the best practices of our best reps that we just wanted to standardize across the entire sales force. This isn't something that the best weren't already doing, but it's how do we have everybody doing the same thing that we have evidence moves the needle.
Right. I think you guys talked about roughly a third of the MACI Arthro-trained surgeon cohort was new to MACI. How is that group ramping compared with new users historically? How much have they contributed to the accelerating biopsy growth we've seen?
Yeah. Just for background, the first year we launched MACI Arthro, it's kind of like when we launched MACI, because implants take lag a while, we would talk about biopsy growth rate and so on. Then we kind of that wasn't the most important thing over time. It was obviously implant growth. For MACI Arthro-trained surgeon, and in the first year, we exceeded our expectations. We got to a critical mass of, call it roughly 1,000 trained surgeons, and they came out of different buckets. We had 5,000 initial MACI Arthro or MACI targets generally, and at that time, about 2,500 were taking biopsies or were sort of MACI users, we call them. Half of those were surgeons who would really just focus, use MACI in the patella or the back of the kneecap because it's a kind of a go-to product there.
The other half of those 2,500 were surgeons who did both patella defects as well as defects on the femoral condyle where MACI Arthro was intended to go, but probably skewed towards bigger defects. Then you had the other half of those 5,000 who hadn't yet engaged, and another couple thousand who were kind of Arthro-only targets that we added. We said in the first year, about a third came of the existing MACI patella users, a third from existing MACI whole knee users, and then a third from either prior open targets or new targets. It's remained that way. I would just say though, the new MACI users, whether they came from the old targets or the new ones, their adoption dynamics are pretty similar to any MACI surgeon who ended up becoming a user.
I would say, we have seen good growth out of, like if I took a subset of the Arthro-only surgeons, we have seen good growth in the number of those surgeons who have either started taking biopsies, so you can track it each year, who have started doing implants. Interestingly, not only do they do MACI Arthro procedures, but they do MACI open procedures as well. It is kind of this halo effect that they may first sort of engage with the brand because they were trained on MACI Arthro, but then a MACI open procedure is pretty easy as well, and they end up actually doing MACI open and MACI Arthro procedures. Obviously that is a very positive dynamic for us.
Mm-hmm. Are you doing anything on the patient side, whether it is education or awareness or support programs to help patients move from biopsy to implant?
Yeah, I would say, generally, because when patients have knee pain, it can be a lot of things. It could be ligament damage, meniscal injuries, or cartilage injuries. We kind of tend not to just do, "Hey, if you have knee pain, go see your doctor and ask about MACI," because most of the time it is probably not a MACI-appropriate patient. What we do is really focus on search engine optimization, whether it is AI-assisted or not. That is kind of prospective patients who have knee pain and have some reason to believe it might be a cartilage injury. Once they sort of move through the funnel and they go see their surgeon, they kind of have a biopsy taken, there are kind of two ways we engage with them.
One is, and probably 50% or more of the cases of a patient that has a biopsy, either at that time or after, they provide a consent form so that we can reach out to them through our marketing team at appropriate times post-biopsy if they have not activated a case and are not moving through or been treated yet. We have other patient resources, patient ambassadors who have been treated with MACI that are open and available for prospective patients to talk to, physical therapists for those who have had a MACI implant and are going through the rehab process. We do a lot more targeted patient engagement through those methods.
Okay. On the U.K., what steps remain between now and, I guess, second half 2027 launch? If anything were to shift that timeline, what would it be?
Yep.
How should we think about that?
Yeah, so just again, taking a step back for a minute, we are about to celebrate our 10-year anniversary with MACI on the market. So, it has been a remarkably strong grower over the first decade it has been on the market. So there is a lot of momentum in the core business. Obviously, with MACI Arthro, that provides other innovation for the product. We will continue to develop additional, and we are working on MACI Arthro V2 versions that make it even simpler and faster to do MACI Arthro procedure, developing instruments, for example, for patella cases, getting behind the kneecap and being able to do that arthroscopically. Outside the U.S., MACI launches as part of our life cycle management, as is MACI Ankle.
The U.K. launch, which we expect to happen in the second half of next year, is really our first step outside the United States. By way of background, MACI was developed in Europe. It was launched in Europe when we bought this business. We were waiting until we had our new facility built in Boston, which has been designed for global manufacturing requirements. Now that that was approved by the FDA earlier this year, the U.K. makes a ton of sense for us to use as a beachhead to go into Europe and other countries. As I said, there is a lot of brand awareness and advocacy because it was on the market there.
In fact, when we launched MACI in the U.S., it was U.K. surgeons that came over and trained the U.S. surgeons because the pivotal study was done in Europe. So great brand awareness and familiarity. They have an expedited approval process for products that have been approved in the U.S., Europe, and Japan. Then a very concentrated sort of commercial effort because in the National Health Service, or the NHS, in the U.K., any patient that is going to do an ACI, like MACI, an autologous chondrocyte implant, have that procedure, they have to go to one of about a dozen specialized joint preservation centers. So that is perfect from a commercial perspective to do that. We submitted our marketing application in the second quarter.
The MHRA did their facility inspection of our new facility in the third quarter, and we expect to have a GMP certification probably before the end of the year. That will be the first step in sort of their review process, which again, is an expedited approval timeline. Then, just last month, we had NICE, which does the pricing and reimbursement for the NHS, agreed to accept MACI for a single technology appraisal. So that is a parallel process for reimbursement and pricing and establishing a budget for the National Health Service in the U.K. Both of those are sort of designed, those tracks to come together sort of early second half of next year, which hopefully will allow us to launch in 2027. So, pretty excited about that, and we have made a lot of progress over the past year there.
Yeah, maybe on that topic, I think you said, what, 15,000 patients, 12 concentrated centers where most of those patients are going to be treated. How do you think, and awareness-
that they know about MACI. How do you think about, I guess, the training ramp that you would be able to do there compared to like what we have seen in the U.S., right? Just one from like a geographic standpoint-
Right
but also just a concentrated center standpoint?
Well, there's probably going to be one or two surgeons at each center that need to be trained. With MACI, generally, surgeons are always going to be trained both for open and arthroscopic procedures. They actually, when we launched MACI, the FDA approves your training materials, and it can be either in person, it can be online. A rep can train them. Here are the steps for a MACI. Really, it's a mini arthrotomy. You're cutting a membrane with cells on it and gluing it in place. That's something any orthopedic surgeon can do, so there's not a heavy training lift. MACI Arthro, same sort of training, different opportunities. They can train on cadavers or not.
So the training lift will be pretty modest from my perspective, given sort of the concentrated number of centers, I don't really think of that as a gating item for adoption.
Okay. Maybe before we touch on the outlook here, burn care, Epicel has been doing good. What initiatives have kind of contributed to that performance, and ultimately, how should we think about the durability?
of kind of what we've seen the past few quarters?
Yeah, burn care obviously has had not only just a good third quarter, but again, growth for the year is kind of up in the 50% range for burn care as a whole. There's been a string of five or six strong quarters. I'd say sort of mid-last year, we the burn care sales organization under a single leader who'd been sort of the sales lead for MACI as well. We restructured the burn care sales force, so we have 17 territories now, where the reps are selling both products, and you see some good benefits in terms of cross-selling two products, both NexoBrid and Epicel. I would say in particular, for Epicel, we called out a couple things for the third quarter that we saw, not only it's the highest quarterly revenue the product has ever had, and it's been on the market for decades.
So a really strong performance there. We had a rebranding of the positioning of the product to really focus on sort of the importance of wound closure. We've had a lot more peer-to-peer trainings and so on around the product. I think we take a different approach every time we get a biopsy. So we always say, we can't control the number of catastrophic burns that occur. We can't control whether patients are going to survive to be treated, but when they are, when we get a biopsy now, we have a multidisciplinary team that works on a treatment plan that the rep then goes and talks to the surgeon about, and that really has enhanced sort of the execution and sort of the pull-through of patients that should be and are able to be treated, actually being treated.
So, up until the first half of this year, I wouldn't say the biopsy growth was kind of the big driver for MACI. It was just great execution on the biopsies and turning those into treatments. Second half of the year, we've actually seen some pretty good growth on the biopsies as well. We mentioned on the call that October had the highest number of biopsies year- to- date. So, if we can combine sort of higher top of the funnel, or a larger top of the funnel with great execution, we think it's pretty sustainable. That process has been institutionalized. Again, we can't control the number of burns and so on, but if they're there to be treated, I think we will maintain that better execution on those patients.
Got it. Joe, maybe just walk us through some of the points or I guess commentary you made on the Q3 call around MACI in 2027, consensus being a good starting point. How should we be thinking about the MACI growth trajectory next year in the context of maybe how you're thinking about the initial guide for the year?
Yeah. We made some comments last week, or a couple weeks ago on the call around guidance. Obviously, a bit early for formal guidance, but just to echo what we talked about a couple weeks ago, number one, as we've been talking about, there is a number of initiatives, again, that we think will be multi-year growth drivers that are going to continue to play out in 2027 from a MACI perspective, really on both franchises. So we are pretty bullish as we move into 2027 based on the indicators and the initiatives. I think we pointed to, when I was asked, from a guidance framework perspective, I would just say what we pointed to is I would expect something pretty similar to what we have done this year, really on both franchises, where I think we have taken a pretty prudent approach.
On MACI in particular, we started the year thinking about kind of similar incremental dollar growth from an initial guide. That is what we pointed to as we move to 2027 as well. I think what was helpful is that is essentially where consensus was coming into the call, so that is something I pointed to, and I think it is essentially around the same spot right now. So, I think that is generally a good starting point, and I think, obviously as we move to next year, we will refine that, but I think we are going to continue to, I would say, generally have higher internal expectations, but from a guidance framework on both franchises remain pretty prudent there.
Got it. Okay. I mean, I guess this is me talking, and you may not be willing to agree here. Like I said, as you think about conservatism having higher internal expectations. But I guess the way I kind of think about it, if you have biopsy growth accelerating each quarter this year, October, I think you said, was one of your strongest months. Q4 apparently seems like biopsies and implant trends are going well. If conversion rates hold, is it realistic to assume that a scenario next year might be accelerating implant growth over what we saw this year?
Yeah. I mean, again, I would say the pieces are in place for a strong year. We do not want to get ahead of ourselves from a guidance perspective, but obviously those are all the things we are focused on, and certainly good to have those indicators all pointing in that direction. I do not see anything else there.
Okay. Then I guess the last one, for the initial guide, or at least how you guys are thinking about the year, is there any reason to believe MACI U.K. revenue would be included? I think you guys have always kind of pointed to that as like a 2028 potential driver. But how should we think about the pacing of that revenue coming online if there is a second half launch?
Yeah. I think to that point, I mean, I think you are thinking about it the right way, which is, if it is a second half launch potentially, then there is a timing element between kind of biopsies and implants. So, I mean, just generally, I would probably think of this more as a 2028 driver at this point, is the right way to think about it.
Okay. Then actually last one here, maybe just puts and takes on EBITDA as we think about 2027. Maybe not on an exact range or a number, but I guess just what should we be thinking about from a sales force leverage perspective, U.K. launch? What are some of the investments that we need to be considering?
Yeah, I mean, generally, Nick referenced it in his opening remarks, but I think Vericel's on track for a very strong year, not only in the top line, but certainly from a bottom line perspective. We increased our full year EBITDA guidance this year, and if you look at that's pointing to a couple hundred basis points in what is really an investment year for us. Whether it's the new facility, the sales force expansion, MACI Ankle, ex-U.S., so a number of investments in 2026. I think I pointed on the call, you could again probably look at where consensus was coming into the call, gives you a sense of a reasonable starting point.
I think we'll be prudent, but I think next year, as we move into 2027, we'll have that sales force expansion in our run rate from an expense perspective. We'll be a little farther along in terms of the multiple facilities. There will be an additional ramp up of the MACI Ankle spend just because that's the way clinical trials work, and obviously we'll be closer in terms of the U.K. and looking at other international markets. But generally, I would say, our expectation is EBITDA's going to continue to tick up, and we feel like we're very much on track for that high 30s by the end of the decade. So, I think 2027 is set up to be another strong year there.
Awesome. We can stop there unless there's any other questions.
Yeah. With your expanded territories leading biopsy growth, what tells you that the growth is permanent volume demand as opposed to pull forward from the initiation of new territory?
Yeah, just so the listeners can hear, the question is, with sort of the expansion territories having the highest growth this year in biopsies, what would lead you to believe that will lead to higher implant growth? I would just say, there's no reason that the conversion rate should be different over time for those new territories. I think that is likely to be seen as we kind of move through the fourth quarter and into next year. So it's a lead with biopsies converting up to 18 months or two years later, you see the ultimate sort of implant growth following by several quarters. But again, there's no reason when a surgeon takes a biopsy for that patient, that there's a with a newer territory or newer rep, that that won't convert as they typically do.
Do the implants continue to grow? Like, once they move from biopsy to implant, the implant volumes, and do you continue or you see, like, an additional bump in implants and then it moderate later? Just trying to figure out, like, once biopsy converts to implant, then is the volume sustainable from there or are you seeing some pull forward?
Yeah. No, there's really no pull forward in our business, whether it's new reps or new territories. I'd say one thing we did point out on our previous earnings call was that, when we have We looked at cohorts of new reps post-COVID, and obviously they contribute in their first year, as we've talked about with this cohort of reps. But really, their growth rates in years two and three tend to lead the nation, essentially, in terms of whether they're legacy territories or new territories. In years two and three, when that pipeline of biopsies they've been developing and growing, they actually start converting into implants in the back half of that year and into the following year, and even stronger growth in year three.
I guess that answers your question, that that growth is actually maintained, increases in both years two and years three is what we've seen from cohorts of new reps. Which is why we think this expansion, the MACI Arthro impact, the commercial excellence initiatives, I mean, they were essentially implemented this year, and we think it's obviously helping to drive the growth. But that's a multi-year set of dynamics, not just a 2026 dynamic.
Any docs talking about Smith & Nephew at all?
Yeah. The question is whether there's any sort of competitive sort of dynamics going on. It's been a bit of a discussion. There's a product out there called Agili-C that's been on the market for about four years now, and will have a permanent CPT code next year. And we've had a lot of discussion around that. It's essentially, and the doc feedback has been similar, that kind of a different patient profile. MACI is used on younger patients with kind of pure cartilage defects, typically no bony involvement. We've looked back and I'd say around 1% of our patients that have been treated with MACI actually have a bone involvement in a small defect, which is typically where, on the femoral condyles, where surgeons expect if they're going to use Agili-C to use it. It's really a different patient population.
We do a lot of surveys. We just completed one of our annual ATU market research projects with 100 surgeons, 50 of which were MACI users, 50 of which were not. And that profile is exactly what we've been talking about, that they expect to use it in patients, older patients, small defects on the femoral condyle with bony involvement. And again, 1%-ish of our patients even fall into that category. We don't see it a lot from sort of our MACI users.
As volumes grow, what costs actually stay fixed with that? Like, stay fixed volume grow and which ones grow with that volume? And does that dynamic change at all as we transition to-
Yeah, the question is what are the fixed costs and what are variables, and what costs grow as MACI increases? There are variable costs associated with MACI. Our gross margins are pretty high already, and that is because we have a fixed manufacturing kind of sales force and infrastructure, and that is why you see huge leverage when our volumes go up in Q4. Our margins get very significant compared to the overall gross margin for the year. The pull-through can be 80%-plus, even higher in some quarters and some years, and that gives you a sense of what the variable component of MACI is. That variable piece are the variable costs that increase when volume increases, but the fixed costs stay the same, which is why we have such strong leverage in our business.
Even as it falls down to the bottom line, to have a 30% adjusted EBITDA margin in a third quarter is pretty significant, and I think last year in the fourth quarter, our adjusted EBITDA margin was around 40%. You see the leverage in the business as volumes grow.
There is no change, like with your Burlington facility, is that going to be more profitable?
No, the move to the Burlington facility, I mean, there are overlapping costs because Epicel is still in the older facility, MACI is in the new one, but again, we have increased our gross margin this year, not as substantially as we have in prior years, but once we get through this transition, we would expect that to continue. Our mid-term goals are high 70%, and we are guiding to 75% this year, so we are really not far away from that, even with two facilities operating. Great. Thank you, guys. Okay, thanks, everyone. Thanks. Appreciate it. Appreciate it.